Bevacizumab-Induced Hypothyroidism: A Case Study

This article presents a case study of a 60-year-old woman with pre-existing primary hypothyroidism whose condition worsened after receiving bevacizumab, a monoclonal antibody targeting VEGF, as part of her chemotherapy regimen for metastatic duodenal carcinoma. The patient experienced elevated TSH levels and symptoms such as fatigue and hair loss, which improved after adjusting her levothyroxine dosage. The study suggests that bevacizumab may exacerbate thyroid dysfunction due to its inhibition of the VEGF signaling pathway, a mechanism not widely reported in the literature. The authors recommend monitoring thyroid function in patients undergoing VEGF inhibitor therapies and call for further research into bevacizumab-induced thyroid dysfunction.